CJC-1295 No DAC (Mod GRF 1-29): Evidence, Mechanism & Legal Status

CJC-1295 without DAC is one of the most-discussed peptides in recovery and longevity circles, almost always alongside ipamorelin. Its mechanism is elegant and genuinely documented; its human clinical case is thin. This monograph separates the proven pharmacology from the hyped human outcomes.2

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. CJC-1295 without DAC is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature and anecdotal use — not as recommendations. Consult a licensed clinician before any health decision.

What is CJC-1295 without DAC and how does it work?

Native growth-hormone-releasing hormone signaling resides in its first 29 residues; GRF(1-29) (sermorelin) retains full GH-releasing activity but is destroyed within minutes in plasma, chiefly by dipeptidyl peptidase IV (DPP-IV) cleavage between residues Ala2 and Asp3, compounded by Asn8 deamidation and Met27 oxidation.1 Mod GRF 1-29 hardens the peptide with four targeted substitutions, which is why it is also called "tetra-substituted GRF(1-29)."12

There is a nomenclature trap worth flagging: some vendors mislabel plain sermorelin (lacking the four substitutions) as "Mod GRF 1-29," and the trade name "CJC-1295 without DAC" is itself a misnomer — the actual CJC-1295 molecule is the DAC bioconjugate, while the "no-DAC" product is simply the tetra-substituted backbone.214 Mechanistically, Mod GRF 1-29 binds the GHRH receptor on anterior-pituitary somatotrophs, a Gs-coupled receptor; activation stimulates adenylyl cyclase, cAMP and protein kinase A, driving synthesis and pulsatile release of growth hormone, which in turn raises hepatic IGF-1.212 Because it works upstream on the body's own somatotrophs, GH output remains subject to negative feedback from IGF-1 and somatostatin, so it cannot drive GH supraphysiologically the way injected recombinant GH can — a key safety distinction, and the reason a functioning pituitary is required for any GHRH agonist to work at all.

The half-life is the headline. The four substitutions extend plasma half-life from the under-10-minutes of native GRF(1-29)/sermorelin to roughly 30 minutes for Mod GRF 1-29 — long enough to provoke a meaningful GH pulse but short enough that GH returns to baseline between doses, preserving the natural pulsatile rhythm.11 Full CJC-1295 instead adds a Drug Affinity Complex (a maleimidopropionic-acid/lysine moiety) that covalently binds circulating albumin, extending half-life to about 5.8 to 8.1 days and producing a multi-day "GH bleed" rather than a pulse.23 The functional trade-off is the entire rationale for the no-DAC form: the pulse keeps GH physiologically rhythmic (theoretically lower insulin-resistance and desensitization risk), whereas the DAC plateau is a continuous, non-pulsatile stimulus.4 Like all GHRH-class peptides it is used parenterally (subcutaneous) in the literature; oral administration is futile because of gut proteolysis.2

What is the evidence by indication?

Bottom line up front: there are no human RCTs of Mod GRF 1-29 (no-DAC) itself. The human-trial evidence in this family tested the DAC version or native GRF(1-29)/sermorelin/tesamorelin. Claims for the no-DAC molecule rest on rat and in-vitro pharmacology (Grade C) and extrapolation or anecdote (Grade D).

The acute GH-release data are solid — in animals. In male Sprague-Dawley rats and cultured rat anterior-pituitary cells the tetra-substituted backbone produced clear, dose-related GH secretion; subcutaneous administration in rats yielded roughly a 4-fold increase in GH area-under-the-curve over 2 hours versus native hGRF(1-29).2 The earlier Hoffmann-La Roche work establishing the substitutions reported the stabilized analogs were about 3 times more potent in vitro and 11 to 13 times more potent in vivo (in pigs) than native GRF, with DPP-IV cleavage completely inhibited over 24 hours.1 This is solid mechanistic proof that the molecule releases GH — in animals, not humans.

The popular human use cases are not in that tier. GH and slow-wave sleep are physiologically linked, and GH/IGF-1 support tissue repair and lipolysis, so the rationale for recovery, sleep and fat-loss benefit is biologically plausible — but there are no controlled human trials of Mod GRF 1-29 demonstrating those outcomes, and the claims are extrapolated from GH physiology, DAC-version pharmacology and user reports.10 The ipamorelin stack rests on genuinely sound pharmacology: somatotrophs carry two independent receptors — the GHRH-R hit by Mod GRF 1-29 and the ghrelin receptor GHS-R1a hit by ipamorelin — and co-activating both produces a synergistic GH pulse, with ipamorelin favored for sparing cortisol, prolactin and ACTH.1213 What is not established by trials is that the specific Mod GRF 1-29 plus ipamorelin stack improves any human clinical endpoint.

For context, the DAC and native-sequence human trials are real but do not transfer. The DAC version raised GH 2-to-10-fold and IGF-1 1.5-to-3-fold for days in healthy adults and was "safe and relatively well tolerated" in a Phase 1 study; details are registered through trial repositories such as ClinicalTrials.gov.3 A separate study showed pulsatility persisted despite continuous DAC stimulation in healthy men (trough GH up about 7.5-fold, mean 24-hour GH up about 46%, n≈21).4 These are DAC data; they support the GHRH-agonist class concept but are not evidence for the short-acting no-DAC product's clinical efficacy.

What doses appear in the literature?

Reported strictly as information, not a protocol. There is no validated human dose. Subcutaneous injection is the universal route in animal studies and anecdotal human use, with the peptide reconstituted from lyophilized powder using bacteriostatic water.211 Reported anecdotal human dosing is commonly cited as about 100 micrograms per injection (a "saturation dose" tied to the GHRH receptor), often once to a few times daily, frequently pre-sleep to align a GH pulse with nocturnal slow-wave sleep, and/or post-exercise, on an empty stomach to avoid blunting the pulse with food or insulin.10 These figures are lay and anecdotal, not trial-derived. The common stack co-administers about 100 to 300 micrograms of ipamorelin in the same syringe, exploiting the GHRH-R plus GHS-R1a synergy; simultaneous (not staggered) dosing is the usual practice.10 Because the half-life is only about 30 minutes, the dose is timed to a desired pulse and clears before the next — deliberately not maintaining a plateau, the opposite of how the once-weekly DAC version is used.11 Product purity, identity and sterility in the research-chemical market are uncontrolled, which is itself a dosing-relevant safety problem.

How safe is CJC-1295 without DAC?

Most reported adverse-effect data come from the DAC and class human studies plus anecdote, since no-DAC trials are absent. Commonly reported, generally mild events in GHRH-class use include injection-site reactions, facial flushing, transient headache and lightheadedness, water retention, and somnolence consistent with a GH pulse.3 The DAC trials reported no serious adverse reactions at the doses tested — but that is short-term, supervised, DAC data and should not be read as a clean bill for chronic no-DAC use.3

The theoretical risks deserve to be taken seriously. Any sustained GH/IGF-1 elevation can be diabetogenic, so insulin resistance and impaired glucose tolerance are real concerns; the no-DAC pulse design theoretically mitigates this versus the DAC plateau, but that benefit is unproven in humans.4 Because IGF-1 is mitogenic, chronically raising the GH/IGF-1 axis carries a theoretical risk of promoting occult or existing malignancy — the central precautionary concern for all GH secretagogues. Acromegaly-type effects are theoretical with chronic supraphysiologic use. Most concretely, the FDA specifically cited immunogenicity, impurities and limited clinical data when flagging this peptide class, and noted cardiac/heart-related reports associated with CJC-1295; unregulated research-chemical product compounds this risk.5 Precautionary contraindications by GH/GHRH-class analogy include active or prior malignancy, pregnancy and lactation, uncontrolled diabetes or significant insulin resistance, active diabetic retinopathy, children and adolescents with open growth plates, and the critically ill.

What is the FDA and WADA status in 2026?

CJC-1295 / Mod GRF 1-29 (no DAC) is not an FDA-approved drug; no NDA or BLA product exists, and the no-DAC form was never developed as a commercial pharmaceutical.14 The compounding timeline is the fast-moving part. On September 29, 2023 the FDA placed roughly 19 peptide bulk substances — including CJC-1295 and ipamorelin — into interim 503A Category 2 ("may present significant safety risks"), citing immunogenicity, impurities, limited clinical data, plus heart-related reports for CJC-1295.5 After 2024 litigation and a settlement that routed several peptides to the Pharmacy Compounding Advisory Committee, the FDA removed CJC-1295, ipamorelin and others from Category 2 in September 2024 — because the nominations were withdrawn, not because they were deemed safe.5 The PCAC reviewed CJC-1295 (free base, acetate and DAC forms) on December 4, 2024 and did not recommend it for the 503A allowed bulks list.5

As of mid-2026 there is no FDA-approved or formally 503A-listed pathway for CJC-1295 / Mod GRF 1-29; PCAC recommendations are non-binding, and formal notice-and-comment rulemaking is required before any peptide is officially added to the allowed list.6 Even reclassification would govern compounding legality only — it would not confer FDA approval, a validated indication, standardized dosing, or established benefit-risk.6 For athletes the picture is unambiguous: CJC-1295 (and CJC-1293, sermorelin, tesamorelin) fall under WADA section S2.2 — Growth Hormone-Releasing Factors (GHRH and analogues) — prohibited at all times, in and out of competition, with ipamorelin and the GHRPs banned in the same section.78 WADA-accredited labs detect these peptides by LC-MS/MS.9 It is not a DEA-scheduled controlled substance, but lack of scheduling does not make human use legal — it remains an unapproved drug.

Bottom line. CJC-1295 without DAC is a well-characterized GHRH-receptor agonist on paper — its tetra-substituted chemistry, ~30-minute half-life and pulse-preserving pharmacology are real and the legitimate reason it differs from full CJC-1295 with DAC and pairs logically with ipamorelin. But the human clinical case is thin: the molecule has been studied in animals and cells (Grade C), never in a published human RCT, and the headline human benefits are anecdotal extrapolations (Grade D). A measured view recognizes the elegant pulse-preserving design while insisting that elegant mechanism is not evidence of human benefit or safety. Regulatory facts here are current as of June 2026 and should be re-verified as the FDA compounding process advances.